Novonix (NVX) Cash & Equivalents (2020 - 2025)

Novonix (NVX) has reported Cash & Equivalents for 6 consecutive years, with $79.9 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 87.67% year-over-year to $79.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $79.9 million (up 87.67% YoY) and the FY2025 annual result came in at $79.9 million, up 87.67% from the prior year.
• Cash & Equivalents slipped to $79.9 million in Q4 2025 per NVX's latest filing, from $112.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NVX reached as high as $183.3 million in Q4 2021 and fell as low as $42.6 million in Q4 2024.
• A 5-year average of $98.5 million and a median of $97.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 261.61% — and 2024, when it tumbled 52.43%.
• Year by year, Cash & Equivalents stood at $183.3 million in 2021, then tumbled by 45.96% to $99.0 million in 2022, then retreated by 20.52% to $78.7 million in 2023, then tumbled by 45.93% to $42.6 million in 2024, then soared by 87.67% to $79.9 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $79.9 million, $112.4 million, and $42.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.